THE AMENDMENT

In The Claims

1. (Withdrawn-Currently Amended) A method for treating cognitive disorders or mnestic disorders which accompany CNS diseases, comprising administering to a patient [[a]] the *R*(+)-2-amino-3-hydroxypropanoic acid derivative according to Claim 8 ~~of formula I~~



~~wherein Ra is a hydrogen;~~

~~Ra' is a hydrogen, a straight or branched chain (C_3-C_6)alkenyl, 3-oxo(C_4-C_6)alkyl, 3-oxo(C_4-C_6)alken-2-yl group, a phenyl(C_1-C_6)alkyl, phenyl(C_2-C_6)alkenyl, gem-diphenyl(C_1-C_6)alkyl, gem-diphenyl(C_2-C_6)alkenyl, *R*(+)-2-aminopropionyl, *S*(-)-2-aminopropionyl, N-(C_2-C_6)alcanoyl-*R*(+)-2-aminopropionyl, N-(C_2-C_6)alcanoyl-*S*(-)-2-aminopropionyl, N-benzyloxycarbonyl-*R*(+)-2-aminopropionyl, N-benzyloxycarbonyl-*S*(-)-2-aminopropionyl, *R*(+)-2,6-diamino-*n*-hexanoyl, *S*(-)-2,6-diamino-*n*-hexanoyl, N,N'-bis-(C_2-C_6)alcanoyl-*R*(+)-2,6-diamino-*n*-hexanoyl, N,N'-(C_2-C_6)alcanoyl-*S*(-)-2,6-diamino-*n*-hexanoyl, N,N'-bis-benzyloxycarbonyl-*R*(+)-2,6-diamino-*n*-hexanoyl, N,N'-bis-benzyloxycarbonyl-*S*(-)-2,6-diamino-*n*-hexanoyl group;~~

~~or Ra and Ra' are together a phenyl(C_1-C_6)alkylydene or gem-diphenyl(C_1-C_6)alkylidene group;~~

~~Ra" is a hydrogen, a straight or branched chain (C_1-C_6)alkyl group or a (C_3-C_6)cycloalkyl(C_1-C_6)alkyl, phenyl(C_1-C_2)alkyl or phenacetyl group;~~

~~the phenyl group or groups present in the substituents Ra, Ra' and Ra" being non-substituted or substituted by a halogen atom or by a hydroxy, (C_1-C_2)alkoxy, cyano, nitro or acetyl group;~~

~~with the proviso that, when Ra and Ra' are both H, then Ra" is other than a hydrogen, (C_1-C_6)alkyl or non-substituted benzyl; or of one of its pharmaceutically acceptable salts~~.

2. (Withdrawn) The method according to claim 1, wherein said CNS disease is schizophrenia.

3. (Withdrawn) The method according to claim 1, wherein said CNS disease is autism.

4. (Withdrawn) The method according to claim 1, wherein said CNS disease is Alzheimer's disease.

5. (Cancelled)

6. (Withdrawn-Currently Amended) A pharmaceutical composition comprising a pharmaceutically effective dose of [[a]] the *R*(+)-2-amino-3-hydroxypropanoic acid derivative according to Claim 8, ~~of formula II~~



(II)

~~wherein Rb is a hydrogen;~~

~~Rb' is a hydrogen, a straight or branched chain (C_3-C_6)alkenyl, 3-oxo(C_4-C_6)alkyl, 3-oxo(C_4-C_6)alken-2-yl group, a phenyl(C_1-C_6)alkyl, phenyl(C_2-C_6)alkenyl, gem-diphenyl(C_1-C_6)alkyl, gem-diphenyl(C_2-C_6)alkenyl, N-(C_2-C_6)alcanoyl-*R*(+)-2-aminopropionyl, N-(C_2-C_6)alcanoyl-*S*(-)-2-aminopropionyl, N-benzyloxycarbonyl-*R*(+)-2-aminopropionyl, N-benzyloxycarbonyl-*S*(-)-2-aminopropionyl, *R*(+)-2,6-diamino-*n*-hexanoyl, *S*(-)-2,6-diamino-*n*-hexanoyl, N,N'-bis-(C_2-C_6)alcanoyl-*R*(+)-2,6-diamino-*n*-hexanoyl, N,N'-(C_2-C_6)alcanoyl-*S*(-)-2,6-diamino-*n*-hexanoyl, N,N'-bis-benzyloxycarbonyl-*R*(+)-2,6-diamino-*n*-hexanoyl, N,N'-bis-benzyloxycarbonyl-*S*(-)-2,6-diamino-*n*-hexanoyl group; or~~

~~Rb and Rb', are together a phenyl(C_1-C_6)alkylydene or gem-diphenyl(C_1-C_6)alkylidene group;~~

~~Rb" is a hydrogen, a straight or branched chain (C_1-C_6)alkyl group or a (C_3-C_6)cycloalkyl(C_1-C_6)alkyl, phenyl(C_1-C_2)alkyl or phenacetyl group;~~

~~the phenyl group or groups present in the Rb, Rb' and Rb" substituents being non-substituted or substituted by a halogen atom or by a hydroxy, (C_1-C_3)alkoxy, cyano, nitro or acetyl group;~~

~~with the proviso that, when Rb and Rb' are both H, then Rb" is other than a hydrogen, (C_1-C_6)alkyl or non-substituted benzyl and that, when Rb is a hydrogen and Rb' is a non-substituted benzyl, a N-benzyloxycarbonyl-*S*(-)-2-aminopropionyl, a *R*(+)-2-aminopropionyl or *S*(-)-2-aminopropionyl, then Rb" is other than hydrogen;~~

or one of its pharmaceutically acceptable salts, in admixture with a pharmaceutically acceptable carrier.

7. (Cancelled)

8. (Currently Amended) A *R*(+)-2-amino-3-hydroxypropanoic acid derivative of formula III, or one of its pharmaceutically acceptable salts;



(III)

wherein R is a hydrogen;

R' is a hydrogen, a phenyl(C_2-C_6)alkenyl, gem-diphenyl(C_1-C_6)alkyl group other than benzhydryl, gem-diphenyl(C_2-C_6)alkenyl; or

R and R', together, form a phenyl(C_1-C_6)alkylidene or gem-diphenyl(C_1-C_6)alkylidene group;

R" is a hydrogen or a (C_1-C_6)alkyl, (C_3-C_6)cycloalkyl(C_1-C_6)alkyl, phenyl(C_1-C_2)alkyl or phenacetyl group;

the phenyl group or groups being non-substituted or substituted by a halogen atom or by a hydroxy, (C_1-C_3)alkoxy, cyano, nitro or acetyl group;

with the proviso that, when R and R' are both hydrogen, then R" is other than a hydrogen, (C_1-C_6)alkyl or non-substituted benzyl~~; or one of its pharmaceutically acceptable salts~~.

9. (Previously Presented) The *R*(+)-2-amino-3-hydroxypropanoic acid derivative according to claim 8, where R' is a ω-diphenyl(C_2-C_6)alkyl group.

10. (Original) *R*(+)-N-(4,4-diphenyl)butyl-2-amino-3-hydroxypropanoic acid or a pharmaceutically acceptable salt thereof.

11. (Original) *R*(+)-N-[(4,4-diphenyl)-3-butenyl]-2-amino-3-hydroxypropanoic acid or a pharmaceutically acceptable salt thereof.

12. (Original) *R*(+)-N-[α-phenyl-(2-hydroxy)benzylidene]-2-amino-3-hydroxypropanoic acid or a pharmaceutically acceptable salt thereof.

13. (Withdrawn) The method according to claim 1, wherein said treatment increases glycinergic transmission in said patient.

14. (New) The *R*(+)-2-amino-3-hydroxypropanoic acid derivative according to claim 8, wherein R' is a phenyl(C_2-C_6)alkenyl.

15. (New) The *R*(+)-2-amino-3-hydroxypropanoic acid derivative according to Claim 8, which is R(+)-N-(4,4-diphenyl)butyl-2-amino-3-hydroxypropanoic acid hydrochloride.

16. (New) The *R*(+)-2-amino-3-hydroxypropanoic acid derivative according to Claim 8, which is R(+)-N-[(4,4-diphenyl)-3-butenyl]-2-amino-3-hydroxypropanoate.